Press Releases April 21, 2026 06:00 AM

Constellium Enters Multi-Year Agreement with Airbus for the Supply of Aluminum Alloy Extrusions

Constellium Secures Long-Term Aluminum Supply Deal with Aerospace Giant Airbus

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CSTM

Constellium SE announced a multi-year supply agreement with Airbus to provide advanced aluminum alloy extrusions, including aluminum-lithium Airware® products, for structural aerospace applications. The deal reinforces Constellium's position as a key supplier in the aerospace market and emphasizes its commitment to quality, industrial reliability, and sustainable manufacturing practices.

Constellium Enters Multi-Year Agreement with Airbus for the Supply of Aluminum Alloy Extrusions
CSTM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Constellium enters multi-year agreement with Airbus to supply advanced aluminum alloy extrusions for aerospace applications.
  • The supply includes bars and various extrusions engineered for high strength-to-weight performance, including proprietary aluminum-lithium Airware® technology.
  • Constellium will supply Airbus from its facilities in France, highlighting its industrial capabilities and recycling expertise in aerospace materials.

PARIS, April 21, 2026 (GLOBE NEWSWIRE) -- Constellium SE (NYSE: CSTM) announced today that it has entered a multi-year agreement with Airbus for the supply of aluminum alloy extrusions, reinforcing our role as a trusted supplier of advanced aluminum solutions for Airbus’ programs and strengthening our long-term partnership.

Under this agreement, Constellium will supply Airbus with a wide range of extrusions manufactured using advanced aluminum alloys, and Constellium’s aluminum-lithium solution, Airware®. The scope includes bars, and a range of small and large extrusions, engineered to meet stringent quality requirements and optimized strength-to-weight performance, supporting demanding aircraft structural applications.

“This agreement reflects Airbus’ trust in our advanced aluminum products and solutions, and in our quality performance, industrial reliability and consistent supply continuity to support long-term aerospace programs,” said Philippe Hoffmann, President of Constellium’s Aerospace and Transportation business unit. “We are committed to continue to grow our outstanding relationship with Airbus, leveraging our comprehensive product portfolio, proprietary solutions, unique manufacturing capabilities, and recycling expertise.”

Constellium will supply Airbus from its facilities in Issoire and Montreuil-Juigné, France.

Constellium is a leading supplier in the aircraft, defense, and space markets. With a broad portfolio of high-performance aluminum products, including its aluminum-lithium solution Airware®, Constellium offers proven industrial and recycling capabilities, as well as cutting-edge technologies to meet the most demanding aerospace applications.

About Constellium

Constellium (NYSE: CSTM) is a global sector leader that develops innovative, value-added aluminum products for a broad scope of markets and applications, including aerospace, packaging and automotive. Constellium generated $8.4 billion of revenue in 2025.

www.constellium.com

Media Contacts  Investor RelationsCommunicationsJason HershiserDelphine Dahan-KocherPhone: +1 443 988-0600Phone: +1 443 420 [email protected]@constellium.com  

Risks

  • Dependence on Airbus demand and aerospace market fluctuations could impact Constellium's revenues and production planning.
  • Potential supply chain disruptions or raw material cost increases could affect the company's ability to fulfill contractual obligations and profitability.
  • Technological or regulatory changes in aerospace materials could require additional investment and adaptation, impacting margins.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026